<p>Revvity Inc. has published the transcript of its Fourth Quarter 2025 Earnings Conference Call, which took place on February 2, 2026. The event featured key members of management, including the Chief Executive Officer, President and Director, the Senior Vice President &amp; Chief Financial Officer, and the Senior Vice President of Investor Relations &amp; Head of ESG. Analysts from Jefferies LLC and Evercore ISI also participated. During the call, management discussed the company’s strong finish to 2025, highlighting both organic growth and strategic initiatives. They emphasized the impact of their collaboration with Lilly TuneLab and the integration of functional AI capabilities, stating, “We can uniquely deliver functional AI capabilities directly to scientists in a completely transformative way.” Additionally, the acquisition of software firm ACD/Labs and a $168 million share repurchase were noted as important steps in capital deployment. The CFO commented on the company’s position, saying, “Our ability to opportunistically deploy capital like we have is a direct result of our strong free cash flow generation and conversion over the last several years since becoming Revvity, combined with our strong balance sheet, both of which I expect to continue.” Management expressed optimism about the future, driven by innovation and expected recovery in key markets. “Revvity is on a strong path with a bright future, especially as key end markets likely continue to recover over the coming months and quarters,” the CEO remarked. The full transcript can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

ARKG

Reuters

Ark Genomic Revolution ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

iShares US Pharma

Direxion Daily LLY Bull 2X Shares

iShares Biotechnology ETF

VG Health

Revvity

First Trust NYSE Arca Biotech Index Fd

Defiance Daily Target 2X Long LLY ETF

Eli Lilly

Invesco Biotechnology & Genome ETF

Revvity Inc. Publishes Transcript of Fourth Quarter 2025 Earnings Call